Article
BRAF mutation predicts sensitivity to MEK inhibition.
Nature - 19 Jan 2006
Solit David B, Garraway Levi A, Pratilas Christine A, Sawai Ayana, Getz Gad, Basso Andrea, Ye Qing, Lobo Jose M, She Yuhong, Osman Iman, Golub Todd R, Sebolt-Leopold Judith, Sellers William R, Rosen Neal
Abstract excerpt
The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members. Using small-molecule inhibitors of MEK and an integrated genetic and pharmacologic analysis, we find that mutation of BRAF is associated with enhanced and selective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.